PDCD1 and cancer: But well-established ICIs, including blockades targeting CTLA-4 and PD-1/PDL-1, only apply to a subset of cancer patients due to heterogeneous gene expressions and microenvironment across various cancer types (6), and as such novel therapeutic targets need to be considered (7, 8).